Drugs / PEGLyte
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06831539 | Dec 2024 → Sep 2026 overdue | cancer | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02976805 | Feb 2017 → Feb 2020 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT01398020 | Jul 2011 → Sep 2012 | — | University of British Columbia | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00380497 Comparator | Sep 2006 → Sep 2007 | colonic duplication | The Hospital for Sick Children | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-Lyte | “Subjects will be asked to take 4L of Peglyte the day prior to procedure.” NCT01398020 ↗ |
| Route | Oral | “Subjects will be asked to take 4L of Peglyte the day prior to procedure.” NCT01398020 ↗ |